摘要
Abstract
Objective To further evaluate the efficacy and safety of rivaroxaban in the thromboprophylaxis after orthopedic surgery.Methods PubMed,EmBase,Cochrane Library,Web of Science,Clinical Trials,CNKI,CBM and Wanfang database were systematically searched.All databases had been searched from established up to August 2016.All randomized controlled trials (RCTs) of rivaroxaban therapy in patients after orthopedic surgery were selected.Meta-analysis was carried out by using RevMan 5.3 software.The incidence of total venous thromboembolism (VTE),major VTE,deep vein thrombosis (DVT),pulmonary embolism (PE),all-cause mortality,symptomatic VTE,bleeding,major bleeding,clinical relevant non-major bleeding (CRNMB),minor bleeding and wound complication were compared and the results were presented with risk ratio (RR) with 95％ confidence interval (CI).Results Totally 32 RCTs of 17061 cases were included in this study,including 9167 cases accepted rivaroxaban (treatment group),other of 7894 cases accepted other drugs (control group).The results of Meta-analysis were as follows.The incidence of symptomatic VTE,total VTE,major VTE and DVT in the rivaroxaban group was lower than that in the low molecular heparin group (P ＜ 0.05).The incidence of total VTE,and DVT in rivaroxaban group was lower than that in aspirin group (P ＜ 0.05).There was no significant difference in the efficacy and safety between the rivaroxaban and apixaban group (P ＞ 0.05).Conclusion In the thromboprophylaxis after orthopedic surgery,efiicacy of rivaroxban is better than that of traditional anticoagulant therapy and it will not increase the risk of adverse events such as bleeding and wound complication.关键词
利伐沙班/静脉血栓栓塞/低分子肝素/阿司匹林/阿哌沙班/Meta分析Key words
rivaroxaban/venous thromboembolism/low molecular heparin/asipirin/apixaban/Meta-analysis分类
医药卫生
